American Journal of Obstetrics & Gynecology
Volume 200, Issue 4 , Pages 347-356 , April 2009

Recent advances in second-trimester abortion: an evidence-based review

Received 31 August 2008 ,Revised 12 October 2008 ,Accepted 9 November 2008.

References 

  1. Connell EB. Preventing the need for second-trimester abortion. In:  Berger G,  Brenner W,  Keith LG editor. Second trimester abortion: perspectives after a decade of experience. Boston: John Wright PSG Inc; 1971;p. 325
  2. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet. 2007;370:1338–1345
  3. Strauss L, Gamble S, Parker W, et al. Abortion surveillance–United States. MMWR Morb Mortal Wkly Rep. 2007;56(SS-91):1–33
  4. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health. 2003;35:16–24
  5. Drey E, Foster D, Jackson R, et al. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynecol. 2006;107:128–135
  6. Finer LB, Frohwirth LF, Dauphinee LA, Singh S, Moore AM. Timing of steps and reasons for delay in obtaining abortions in the United States. Contraception. 2006;74:334–344
  7. Medical methods for termination of pregnancy: report of WHO scientific group (Technical report series, No. 871). Geneva, Switzerland: World Health Organization; 1997;
  8. Grimes DA, Schulz KF, Cates WJ. Prevention of uterine perforation during curettage abortion. JAMA. 1984;251:2108–2111
  9. Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol. 2004;104:174–185
  10. Tietze C, Henshaw SK. Induced abortion: a world review. 3rd ed.. New York: Alan Guttmacher Institute; 1986;
  11. Kafrissen ME, Schulz KF, Grimes DA, et al. Midtrimester abortion: intra-amniotic instillation of hyperosmolar urea and prostaglandin 5 2 alpha versus dilatation and evacuation. JAMA. 1984;251:916–919
  12. Grimes DA, Schulz KF, Cates W, et al. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. N Engl J Med. 1977;296:1141–1145
  13. Hern WM. Serial multiple laminaria and adjunctive urea in late outpatient dilatation and evacuation abortion. Obstet Gynecol. 1984;63:543–549
  14. Peterson WF, Berry N, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol. 1983;62:185–190
  15. Lawson HW, Frye A, Atrash HK, et al. Abortion mortality, United States, 1972-1987. Am J Obstet Gynecol. 1994;171:1365–1372
  16. Hoyert DL. Maternal mortality and related concepts: National Center for Health Statistics. Vital Health Stat. 2007;3:33
  17. Kalish RB, Chasen ST, Rosenzweig LB, Rashbaum WK, Chervenak FA. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol. 2002;187:882–885
  18. Jackson JE, Grobman WA, Haney E, Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gynaecol Obstet. 2007;96:12–15
  19. Freeman EW. Abortion: subjective attitudes and feelings. Fam Plann Perspect. 1978;10:150–155
  20. Rooks JB, Cates W. Emotional impact of D and E vs instillation. Fam Plann Perspect. 1977;9:276–277
  21. Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol. 1979;135:235–238
  22. Cowett A, Golub R, Grobman W. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol. 2006;194:768–773
  23. Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomized controlled trial. BJOG. 2004;111:148–153
  24. Eastwood KL, Kacmar JE, Steinauer J, Weitzen S, Boardman LA. Abortion training in the United States obstetrics and gynecology residency programs. Obstet Gynecol. 2006;108:303–308
  25. Henshaw SK. Factors hindering access to abortion services. Fam Plann Perspect. 1995;27:54–59
  26. MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766–770
  27. Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod. 1999;14:2139–2142
  28. El-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet. 1994;343:1207–1209
  29. Bugalho A, Bique C, Almeida L, Bergstrom S. Application of vaginal misoprostol before cervical dilatation to facilitate first trimester pregnancy interruption. Obstet Gynecol. 1994;83:729–731
  30. Todd CS, Soler M, Castleman L, Rogers MK, Blumenthal PD. Buccal misoprostol for second trimester pregnancy termination. Contraception. 2002;65:415–418
  31. Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception. 2006;73:420–430
  32. Goldberg A, Drey E, Whitaker A, Kang M, Meckstroth K, Darney P. Misoprostol compared with laminaria before early second trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005;106:234–241
  33. Edelman A, Buckmaster J, Goetsch M, Nichols M, Jensen J. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. Am J Obstet Gynecol. 2006;194:425–430
  34. Darney PD, Dorward K. Cervical dilation before first-trimester elective abortion: a controlled comparison of meteneprost, laminaria and hypan. Obstet Gynecol. 1987;70:397–400
  35. Chen JK, Elder MG. Preoperative cervical dilatation by vaginal pessaries containing prostaglandin E1 analogue. Obstet Gynecol. 1983;62:339–342
  36. Lauersen HN, Den T, Iliescu C, et al. Cervical priming prior to dilatation and evacuation: a comparison of methods. Am J Obstet Gynecol. 1982;14:890–894
  37. Carbonell J, Gallego F, Llorente M, et al. Vaginal vs sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial. 2007;75:230–237
  38. Riddle J. Contraception and abortion from the ancient world to the Renaissance. In: Cambridge, MA: Harvard University Press; 1992;p. 7–9
  39. Potts M. Foreward. In:  Baird D,  Grimes D,  Van Look P editor. Modern methods of inducing abortion. London: Blackwell Science Ltd; 1995;p. ix
  40. Kafrissen ME, Barke MW, Workman P, et al. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol. 1983;147:344–345
  41. Kapp N, Todd CS, Yadgarova KT, et al. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2 analogue for second trimester induction termination in Uzbekistan. Contraception. 2007;76:461–466
  42. Herabutya Y, O-Prasertsawat P. Mid-trimester abortion using hypertonic saline or prostaglandin E2 gel: an analysis of efficacy and complications. J Med Assoc Thai. 1994;77:148–152
  43. Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol. 2005;193(Suppl1):S1065–S1070
  44. Peyron R, Aubeny E, Targosz V, et al. Early termination of pregnancy with mifepristone (Ru-486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509–1513
  45. Andersen LF, Poulsen HK, Sorensen SS, Christensen BM, Sponland G, Skjeldestad FE. Termination of 2nd trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic Pgf2-alpha: a comparative study. Eur J Obstet Gynecol Reprod Biol. 1989;31:1–7
  46. Cameron IT, Baird DT. The use of 16,16-dimethyl-trans-delta-2 prostaglandin-E1 methyl-ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early 2nd trimester: a comparison with extra-amniotic prostaglandin-E2. Br J Obstet Gynaecol. 1984;91:1136–1140
  47. Su LL, Biswas A, Choolani M, Kalaichelvan V, Singh K. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol. 2005;193:1410–1414
  48. Owen J, Hauth JC. Vaginal misoprostol vs concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med. 1999;8:48–50
  49. Nor Azlin M, Abdullah H, Zainul Rashid M, Jamil M. Misoprostol (alone) in second trimester terminations of pregnancy: as effective as gemeprost?. J Obstet Gynaecol. 2006;26:546–549
  50. Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki AE. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet Gynecol. 1997;90:896–900
  51. Wong KS, Ngai CSW, Wong AYK, Tang LCH, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomized trial. Contraception. 1998;58:207–210
  52. Dodd CM, Crowther CA. Misoprostol versus cervagem for the induction of labor to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2006;125:3–8
  53. Marinoni E, Santoro M, Vitagliano MP, Patella A, Cosmi EV, Di Iorio R. Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus. Int J Gynaecol Obstet. 2007;97:35–39
  54. Neilson JP, Hickey M, Vasquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2006;3:OD002253
  55. Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update. 2007;13:37–52
  56. Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: a review. Obstet Gynecol. 2002;99:316–332
  57. Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med. 1994;331:290–293
  58. Herabutya Y, Prasertsawat PO. Second trimester abortion using intravaginal misoprostol. Int J Gynaecol Obstet. 1998;60:161–165
  59. Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second trimester pregnancy termination. Am J Obstet Gynecol. 2002;186:470–474
  60. Ramin KD, Ogburn PL, Daninlenko DR, Ramsey PS. High-dose oral misoprostol for mid-trimester pregnancy interruption. Gynecol Obstet Invest. 2002;54:176–179
  61. Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol. 2002;187:853–857
  62. Wong KS, Ngai CSW, Yeo ELK, Tang LCH, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod. 2000;15:709–712
  63. Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de LR, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet. 2007;99(Suppl2):S178–S181
  64. Ashok PW, Templeton A, Wagaarachchi PT, Flett GMM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004;69:51–58
  65. Borgatta L, Chen AY, Vragovic O, Stubblefield PG, Magloire CA. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception. 2005;72:358–361
  66. Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet. 2004;87:176–177
  67. Berger GS, Kerenyi TD. Analysis of retained placenta associated with saline abortion: clinical considerations. Am J Obstet Gynecol. 1974;120:484–488
  68. Kirz DS, Haag MK. Management of the 3rd stage of labor in pregnancies terminated by prostaglandin-E2. Am J Obstet Gynecol. 1989;160:412–414
  69. Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception. 2007;76:310–313
  70. United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program for Research and Development and Research Training in Human Reprod. Annual technical report 1997. Geneva, Switzerland: World Health Organization; 1998;
  71. World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva, Switzerland: World Health Organization; 2003;
  72. Royal College of Obstetricians and Gynecologists. The care of women requesting induced abortion. London: Royal College of Obstetricians and Gynecologists; 2004;
  73. Bygdeman M, Swahn ML. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception. 1985;32:45–51
  74. Tang OS, Chan CCW, Kan ASY, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod. 2005;20:3062–3066
  75. Rose SB, Shand C, Simmons A. Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases. Aust N Z J Obstet Gynaecol. 2006;46:479–485
  76. El-Rafaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod. 1995;10:475–478
  77. Nigam A, Singh VK, Prakash A. Vaginal vs oral misoprostol for mid-trimester abortion. Int J Gynaecol Obstet. 2006;92:270–271
  78. Tang OS, Lau W, Chan C, Ho PC. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004;111:1001–1005
  79. Webster D, Penney GC, Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynaecol. 1996;103:706–709
  80. World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993;307:532–537
  81. Heikinheimo O, Suhonen S, Haukkamaa M. One- and two-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online. 2004;8:236–239
  82. Nilas L, Glavind-Kristensen M, Vejborg T, Knudsen UB. One or two day mifepristone-misoprostol interval for second trimester abortion. Acta Obstet Gynecol Scand. 2007;86:1117–1121
  83. Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced midtrimester abortion. Hum Reprod. 1990;5:883–886
  84. Kapp N, Borgatta L, Stubblefield PG, Vragovic O, Moreno N. Mifepristone in midtrimester medical abortion: a randomized controlled trial. Obstet Gynecol. 2007;110:1304–1310
  85. Jain JK, Mishell DR. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol. 1996;175:173–177
  86. Thong KJ, Baird DT. A study of gemeprost alone, Dilapan or mifepristone in combination with gemeprost for the termination of 2nd trimester pregnancy. Contraception. 1992;46:11–17
  87. Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. BJOG. 1999;106:706–710
  88. Bartley J, Baird DT. A randomized study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG. 2002;109:1290–1294
  89. Hamoda H, Ashok PW, Flett GMM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod. 2005;20:2348–2354
  90. Eng NS, Guan AC. Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. Aust N Z J Obstet Gynaecol. 1997;37:331–334
  91. Dickinson JE, Godfrey M, Evans SF. Efficacy of intravaginal misoprostol in second trimester pregnancy termination: a randomized controlled trial. J Matern Fetal Med. 1998;7:115–119
  92. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect. 1995;27:142–148
  93. Winikoff B, Sivin I, Coyaji KL, et al. Safety, efficacy and acceptability of medical abortion in China, Cuba and India: a comparative trial of mifepristone-misoprostol vs surgical abortion. Am J Obstet Gynecol. 1997;176:431–437
  94. Howie FL, Henshaw FC, Naji SA, Russell IT, Templeton AA. Medical abortion or vacuum aspiration? (Two year follow up of a patient preference trial). BJOG. 1997;104:829–833
  95. Clark W, Shannon C, Winikoff B. Misoprostol for uterine evacuation in induced abortion and pregnancy failure. Expert Rev Obstet Gynecol. 2007;2:67–108
  96. Wagaarachchi PT, Ashok PW, Narvekar NN, Smith NC, Templeton A. A medical management of late intrauterine death using a combination of mifepristone and misoprostol. Br J Obstet Gynaecol. 2002;109:443–447
  97. Fairley TE, Mackenzie M, Owen P, Mackenzie F. Management of late intrauterine death using a combination of mifepristone and misoprostol–experience of two regimens. Eur J Obstet Gynecol Reprod Biol. 2005;118:28–31
  98. Jannet D, Aflak N, Abankwa A, Carbonne B, Marpeau L, Milliez J. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur J Obset Gynecol Reprod Biol. 1996;70:159–163
  99. Jackson RA, Teplin VL, Drey EA, Thomas LJ, Darney PD. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001;97:471–476
  100. Hern WM, Zen C, Ferguson KA, Hart FV, Haseman MV. Outpatient abortion for fetal anomaly and fetal death from 15-34 menstrual weeks gestation–techniques and clinical management. Obstet Gynecol. 1993;81:301–306
  101. Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second trimester abortion. Obstet Gynecol. 1999;94:139–141
  102. Molaei M, Jones HE, Weiselberg T, McManama M, Bassell J, Westhoff CL. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception. 2008;77:223–225
  103. Rouzi AA. Second trimester pregnancy termination with misoprostol in women with previous cesarean sections. Int J Gynaecol Obstet. 2003;80:317–318
  104. Debby A, Golan A, Sagiv R, et al. Midtrimester abortion in patients with a previous uterine scar. Eur J Obstet Gynecol Reprod Biol. 2003;109:177–178
  105. Pongsatha S, Tongsong T. Misoprostol for second trimester termination of pregnancies with prior low transverse cesarean section. Int J Gynaecol Obstet. 2003;80:61–62
  106. Dickinson JE. Misoprostol for second trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol. 2005;105:352–356
  107. Bhattacharjee N, Ganguly R, Sha S. Misoprostol for termination of mid-trimester post-cesarean pregnancy. Aust N Z J Obstet Gynaecol. 2007;47:23–25
  108. Daponte A, Nzewenga G, Dimopoulos KD, Guidozzi F. The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. Contraception. 2006;74:324–327
  109. Shammas AG, Momani MD. Misoprostol for termination of second trimester pregnancy in a scarred uterus. Saudi Med J. 2006;27:1173–1176
  110. Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous cesarean section. Contraception. 2006;73:244–248
  111. Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior cesarean section. BJOG. 2005;112:97–99
  112. Thomas AG, Alvarez M, Friedman F, Brodman ML, Kim J, Lockwood C. The effect of placenta previa on blood loss in second-trimester pregnancy termination. Obstet Gynecol. 1994;84:58–60
  113. Nakayama D, Masuzaki H, Miura K, et al. Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost. Contraception. 2007;75:238–240
  114. Thong KJ, Robertson AJ, Baird DT. A retrospective study of 932 second trimester terminations using gemeprost (16,16-dimethyl-trans delta2 PGE1 methyl ester). Prostaglandins. 1992;44:65–74
  115. Shulman LP, Ling FW, Meyers CM, Shanklin DR, Simpson JL, Elias S. Dilation and evacuation for second-trimester genetic pregnancy termination. Obstet Gynecol. 1990;75:1037–1040
  116. McMahon JT. Intact D&E: the first decade. Presented at: National Abortion Federation Conference; New Orleans, LA, April 2, 1995. Oral presentation.
  117. Haskell M. Dilation and extraction for late second trimester abortion. Presented at: National Abortion Federation Risk Management Seminar. Dallas, TX, September 13, 1992. Oral presentation.
  118. Chasen ST, Kalish RB, Gupta M, Kaufman JE, Rashbaum WK, Chervenak FA. Dilation and evacuation at > or=20 weeks: comparison of operative techniques. Am J Obstet Gynecol. 2004;190:1180–1183

 Reprints not available from the author.

PII: S0002-9378(08)02214-X

doi: 10.1016/j.ajog.2008.11.016

American Journal of Obstetrics & Gynecology
Volume 200, Issue 4 , Pages 347-356 , April 2009

Article Tools

* Image Usage & Resolution